编辑专栏文章 - 后台系统

编辑专栏文章

编辑专栏文章

文章标题：

标　　签：

关键字：

文章分类：

文章主图*

点击“Select image”更换图片

Select image Change Remove

注意! 最佳图片尺寸800*800

内容详情：

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">靶向新药</font></span></span></span></span><a href="http://www.india-drugstore.com/p/zhuanti_detail.php?id=1914"><span style="color:#3498db;"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑"><strong><span style="background-color:#f1c40f;">莫博替尼</span></strong></font><font face="微软雅黑"><strong><span style="background-color:#f1c40f;">TAK-788</span></strong></font></span></span></span></span></a><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">在先前接受治疗的EGFR ex20ins阳性mNSCLC患者中具有良好的风险-效益特征。莫博替尼</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">是一种强效小分子酪氨酸激酶抑制剂，能够有针对性地靶向作用于EGFR和HER2 20号外显子插入突变。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">根据</font><font face="微软雅黑">2021年ASCO会议上公布的数据，96例局部晚期/转移性EGFR ex20ins NSCLC患者，所有患者每天一次口服</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">TAK788（160mg）。 中位治疗时间为6.5个月，独立审查委员会（IRC）评估的客观有效率（ORR）为25%，疾病控制</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">率DCR为76%[95%CI:66-84]；未达到DOR中位数，PFS为7.3个月，中位OS尚未到达；114例既往接受过铂类治疗的患</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">者，接受TAK-788中位治疗时间为7个月，IRC确认的ORR为28%，疾病控制率（DCR）为78%[95%CI:69–85]，中位反</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">应持续时间（DOR）为17.5个月，中位PFS为7.3个月，中位生存期（OS）为24个月。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p align="justify" class="p" style="margin-top:0.0000pt; margin-right:0.0000pt; margin-bottom:0.0000pt; margin-left:0.0000pt; padding:0pt 0pt 0pt 0pt ; text-align:justify; margin:5pt 0pt"><span style="font-size:12pt"><span style="background:#ffffff"><span style="text-justify:inter-ideograph"><span style="line-height:12.0000pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">试验结果显示，莫博替尼对先前接受治疗的</font><font face="微软雅黑">EGFR ex20ins阳性转移性非小细胞</font></span></span></span></span></span></span></span><a href="https://www.cancer123.com/types/lung-cancer/"><span class="15" style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">肺癌</font></span></span></span></span></span></span></span></a><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">患者有临床意义的生存益处，而且安</font></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p align="justify" class="p" style="margin-top:0.0000pt; margin-right:0.0000pt; margin-bottom:0.0000pt; margin-left:0.0000pt; padding:0pt 0pt 0pt 0pt ; text-align:justify; margin:5pt 0pt"> </p>

<p align="justify" class="p" style="margin-top:0.0000pt; margin-right:0.0000pt; margin-bottom:0.0000pt; margin-left:0.0000pt; padding:0pt 0pt 0pt 0pt ; text-align:justify; margin:5pt 0pt"><span style="font-size:12pt"><span style="background:#ffffff"><span style="text-justify:inter-ideograph"><span style="line-height:12.0000pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">全状况可控。</font></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p align="justify" class="p" style="margin-top:0.0000pt; margin-right:0.0000pt; margin-bottom:0.0000pt; margin-left:0.0000pt; padding:0pt 0pt 0pt 0pt ; text-align:justify; margin:5pt 0pt"> </p>

<p align="justify" class="p" style="margin-top:0.0000pt; margin-right:0.0000pt; margin-bottom:0.0000pt; margin-left:0.0000pt; padding:0pt 0pt 0pt 0pt ; text-align:justify; margin:5pt 0pt"><span style="font-size:12pt"><span style="background:#ffffff"><span style="text-justify:inter-ideograph"><span style="line-height:12.0000pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑"><img alt="" src="../upload/658a9d2548fc7687450927.jpg" style="width: 200px; height: 267px;" /></font></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p align="justify" class="p" style="margin-top:0.0000pt; margin-right:0.0000pt; margin-bottom:0.0000pt; margin-left:0.0000pt; padding:0pt 0pt 0pt 0pt ; text-align:justify; margin:5pt 0pt"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

首页显示：

显示不显示

热门文章：

是否

阅读：